Clinical Trials Logo

Glioblastoma clinical trials

View clinical trials related to Glioblastoma.

Filter by:

NCT ID: NCT00589875 Completed - Clinical trials for Glioblastoma Multiforme

Phase 2a Study of CAN-2409 With Standard Radiation Therapy for Malignant Glioma

BrTK02
Start date: March 2007
Phase: Phase 2
Study type: Interventional

The purpose of this study was to evaluate the safety and potential efficacy of CAN-2409 (also known / previously described as AdV-tk, GMCI) for malignant gliomas. The approach used an adenoviral vector (disabled virus) engineered to express the Herpes thymidine kinase gene (aglatimagene besadenovec, CAN-2409), followed by an antiherpetic prodrug, valacyclovir. CAN-2409 was injected into the resection bed after standard tumor surgery and valacyclovir pills were taken for 14 days. Standard radiation and chemotherapy were administered which have been shown to work cooperatively with CAN-2409 + prodrug to kill tumor cells. The hypothesis is that this combination therapy can be safely delivered and will lead to improvement in the clinical outcome for patients with newly diagnosed malignant gliomas, including glioblastoma multiforme (WHO grade IV) and anaplastic astrocytomas (WHO grade III).

NCT ID: NCT00589095 Terminated - Clinical trials for Glioblastoma Multiforme

Early Detection of Glioblastoma Multiforme (GBM) Treatment Responses Using Multiple Magnetic Resonance Modalities

Start date: November 2006
Phase: N/A
Study type: Observational

The purpose of this study is to determine whether dynamic contrast enhanced MRI (DCE MRI) and high diffusion weighting MRI may be used to distinguish between favorable and unfavorable responses to therapy of glioblastoma multiforme. Imaging data will be correlated with histopathologic findings and clinical responses to radiation therapy with or without chemotherapy.

NCT ID: NCT00586508 Completed - Clinical trials for Recurrent Glioblastoma

Trial of Enzastaurin and Bevacizumab in Participants With Recurrent Malignant Gliomas

Start date: November 2007
Phase: Phase 2
Study type: Interventional

The purpose of this study is to evaluate both enzastaurin and bevacizumab in the treatment of recurrent malignant gliomas.

NCT ID: NCT00584883 Completed - Brain Tumor Clinical Trials

A Phase I Study of ABT 510 for Newly Diagnosed Glioblastoma Multiforme

Start date: August 2003
Phase: Phase 1
Study type: Interventional

To determine the maximum tolerated dose of ABT 510 when administered concurrent with radiation therapy for patients with newly diagnosed glioblastoma multiforme.

NCT ID: NCT00576641 Completed - Glioblastoma Clinical Trials

Immunotherapy for Patients With Brain Stem Glioma and Glioblastoma

Start date: May 2007
Phase: Phase 1
Study type: Interventional

The purpose of the Dendritic Cell Immunotherapy study for patients with glioblastoma and/or brainstem glioma is to determine whether in patients with malignant brain tumors, dendritic cells injected peripherally can reactivate the immune system against the brain tumor.

NCT ID: NCT00576537 Completed - Glioblastoma Clinical Trials

Tumor Lysate Pulsed Dendritic Cell Immunotherapy for Patients With Brain Tumors

Start date: March 2001
Phase: Phase 2
Study type: Interventional

This research is being determine whether vaccinations with your own immune cells called " dendritic cells " can activate your immune system to fight your brain tumor.

NCT ID: NCT00575887 Completed - Glioblastoma Clinical Trials

Efficacy of Protracted Temozolomide in Patients With Progressive High Grade Glioma

Start date: August 2006
Phase: Phase 2
Study type: Interventional

The purpose of this study is to evaluate the efficacy of temozolomide on a protracted schedule, after standard 5-day temozolomide regimen in patients with recurrent or progressive high grade glioma.

NCT ID: NCT00575146 Completed - Clinical trials for Recurrent Glioblastoma

Ketogenic Diet for Recurrent Glioblastoma

ERGO
Start date: December 2007
Phase: Phase 1
Study type: Interventional

To determine whether a mild ketogenic diet can influences quality of life and survival of patients with recurrent glioblastoma

NCT ID: NCT00574964 Terminated - Clinical trials for Primary Glioblastoma Multiforme

Gliadel Wafers and Temodar in the Treatment of Glioblastoma Multiforme

Temodar
Start date: October 2005
Phase: Phase 2
Study type: Interventional

The purpose of this research study is to determine if combining all three treatments of Gliadel wafers, Temozolomide and Radiation therapy at the same time is safe and more effective than one treatment at a time. The study will measure the survival of subjects treated with this combination of drugs.

NCT ID: NCT00562419 Active, not recruiting - Clinical trials for Brain and Central Nervous System Tumors

CT-322 in Treating Patients With Recurrent Glioblastoma Multiforme and Combination Therapy With Irinotecan

Start date: October 2007
Phase: Phase 2
Study type: Interventional

RATIONALE: CT-322 may stop the growth of glioblastoma multiforme by blocking blood flow to the tumor. Drugs used in chemotherapy, such as irinotecan, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. Giving CT-322 together with irinotecan may kill more tumor cells. PURPOSE: This phase 2 trial is studying the side effects, tolerability, and efficacy of CT-322 when given alone and in combination with irinotecan to patients with glioblastoma multiforme.